**Amendments to the Claims:**

This listing of claims replaces all prior versions and listings of claims in the application:

**Listing of Claims:**

Claim 1. (Previously Presented): A topical water-in-oil pharmaceutical ~~cream, composition~~ cream composition for the treatment of inflammation comprising:

a) 0.01 to 0.25 percent Mometasone Furoate;
b) 10 to 30 percent propylene glycol;
c) 1.0 to 5 percent water;
d) 2.0 to 10.0 percent white wax;
e) 4.0 to 12.0 percent of a lipophilic surfactant having an HLB value of less than 6;
f) 0.7 to 4.0 percent of a hydrophilic surfactant having an HLB value of greater than 10;
g) 0.2 to 2.0 percent Titanium dioxide;
h) 5.0 to 20.0 percent aluminum starch octenylsuccinate;
i) 40 to 70 percent white petrolatum; and
j) sufficient acid to adjust the pH of the water wherein said composition has a viscosity of about 400,000 to about 900,000 centipoise.

Claim 2. (Original): The topical pharmaceutical composition of claim 1 wherein the lipophilic surfactant is selected from the group consisting of propylene glycol stearate, ethylene glycol monolaurate, ethylene glycol monostearate, propylene glycol monolaurate and glyceryl monoricinolate.

Claim 3. (Original): The topical pharmaceutical composition of claim 1 wherein the hydrophilic surfactant is selected from the group consisting of stearyl alcohol and ceteareth-20, polyethylene glycol monolaurate, polyethylene glycol distearate, polyoxyethylene cetyl alcohol,

polyoxyethylene sorbitan monostearate and polyoxyethylene sorbitan monooleate.

Claim 4. (Original): The topical pharmaceutical composition of claim 1 wherein the acid utilized to adjust the pH of the water is selected from the group consisting of phosphoric acid, hydrochloric acid, and acetic acid.

Claim 5. (Previously Presented): A topical water-in-oil pharmaceutical cream composition for the treatment of inflammation comprising:

a) 0.10 percent Mometasone Furoate;
b) 22.50 percent propylene glycol;
c) 2.59 percent water;
d) 3 percent white wax;
e) 6 percent of propylene glycol stearate;
f) 1.35 percent of ceteareth-20;
g) 2.0 percent Titanium dioxide;
h) 10 percent aluminum starch octenylsuccinate;
i) 51.8 percent white petrolatum; and
j) sufficient phosphoric acid to adjust the pH of the water to wherein said composition has a viscosity of about 650,000 to about 825,000 centipoise.

Claim 6. (New): A method for treating a patient suffering from inflammation of the skin, comprising:

applying a layer of the topical water-in-oil pharmaceutical cream of claim 1 to the inflamed skin of the patient; and

allowing the layer of the topical water-in-oil pharmaceutical cream to remain on the skin for a duration effective to reduce the inflammation.

Claim 7. (New): The method of claim 6, wherein the topical water-in-oil pharmaceutical cream does not irritate the skin.

Claim 8. (New): A method for treating a patient suffering from inflammation of the skin, comprising:

applying a layer of about 10 μl of the topical water-in-oil pharmaceutical cream of claim 1 to the inflamed skin of the patient; and

allowing the layer of the topical water-in-oil pharmaceutical cream to remain on the skin for about 1 hour.

Claim 9. (New): The method of claim 8, wherein the topical water-in-oil pharmaceutical cream does not irritate the skin during the time the topical water-in-oil pharmaceutical cream remains on the skin.